Abstract

Provided is an animal biological information measurement device that allows an electrode to be placed at a desired position on the body of an animal. Provided is an animal biological information measurement system comprising the animal biological information measurement device. Provided is an animal biological information measurement method using the animal biological information measurement system.　An animal biological information measurement device (1) comprises: a substrate (2); an electrode (3) that is provided on the substrate (2) and is used for acquisition of biological information of an animal in contact with the electrode (3); and a grip member (4) that is connected to the substrate (2) and grips hair of the animal.

IPC Classes  ?

• A61D 13/00 - Thermometer holders specially adapted to veterinary purposes
• A01K 29/00 - Other apparatus for animal husbandry
• A61B 5/254 - Means for maintaining electrode contact with the body by clips
• A61B 5/256 - Wearable electrodes, e.g. having straps or bands
• A61B 5/265 - Bioelectric electrodes therefor characterised by the electrode materials containing silver or silver chloride

Abstract

It is an object of the present invention to provide a vaccine effective for protection against infection by Streptococcus species that causes mastitis in livestock and other animals. Specifically, the present invention provides a vaccine comprising a non-encapsulated strain of Streptococcus species as an antigen, and in particular, a vaccine for preventing mastitis developed by infection by Streptococcus uberis.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

A comprehensive search for pancreatic cancer biomarkers revealed that REEP5 is a marker specific to pancreatic cancer. It was also clear that pancreatic cancer can be detected with favorable sensitivity by REEP5 even by the ELISA commonly used in clinical settings. Moreover, pancreatic cancer can be detected with greater sensitivity by measuring fucosylated REEP5 and the ratio of fucosylated REEP5/REEP5. Analysis of fucosylated REEP5 and the ratio of fucosylated REEP5/REEP5 at the different stages of pancreatic cancer showed a tendency toward higher expression during early pancreatic cancer, and therefore the present invention provides an effective marker for early detection of pancreatic cancer, for which there was not an effective marker until now.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The purpose of the present invention is to provide a method and a device for improving the physiological state of a bred animal.　The present invention improves the physiological state of a bred animal by using a light-emitting device to emit, onto the bred animal, light of a specific wavelength region such as violet light, the light being emitted so as to blink at a prescribed blinking frequency, for example.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry

Abstract

An objective of one embodiment of the present invention is to provide a method capable of continuously and simply reducing the number of bacteria, fungi and viruses on livestock sheds and body surfaces of livestock (dairy cows, beef cows, pigs, horses, etc.) exposed to a large amount of organic substances such as excrement, thereby reducing the risk of livestock disease. A method for reducing disease risk according to one embodiment of the present invention includes a step for bringing an aqueous solution in which a quaternary ammonium salt-based coupling agent is dissolved into contact with the body surface of livestock.

IPC Classes  ?

• A61K 31/695 - Silicon compounds
• A01N 25/24 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
• A01N 33/12 - Quaternary ammonium compounds
• A01P 3/00 - Fungicides
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Methane production from ruminant digestion is reduced by allowing a ruminant to be fed on feed containing unfermented coffee grounds.

IPC Classes  ?

• A61K 36/74 - Rubiaceae (Madder family)
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation. There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation. A method for evaluating allergen inactivators, said method being characterized by comprising: a step for preparing an allergen-supporting membrane configured by supporting allergens on a membrane for supporting allergens; a step for treating the allergen-supporting membrane using a test drug; a step for washing the allergen-supporting membrane treated using the test drug, and subsequently treating the allergen-supporting membrane using antibodies specific to the allergens; a step for washing the allergen-supporting membrane treated using the antibodies specific to the allergens, and subsequently detecting the specific antibodies bound to the allergens; and a step for assessing the extent to which the allergens are inactivated by the test drug based on the detected quantity of the specific antibodies.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic

Abstract

22 represents a hydrogen or a hydroxyl group; and X represents a carrier protein.]

IPC Classes  ?

• C12P 21/08 - Monoclonal antibodies
• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens
• C07D 493/10 - Spiro-condensed systems

Abstract

The present invention is intended to provide a lactic acid bacterium-containing composition that is effective for suppression of the onset of allergies. More specifically, the present invention relates to a composition comprising lactic acid bacteria belonging to Lactobacillus animalis, wherein the composition is provided in the form of, for example, a food or beverage composition, a pharmaceutical composition, a feed composition, a sanitary composition or the like. Furthermore, the present invention provides a method for preventing the onset of allergies.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12N 1/20 - BacteriaCulture media therefor
• A61P 37/08 - Antiallergic agents
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Streptococcus uberisStreptococcus uberis infection.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention addresses the problem of providing a composition containing poly(D-3-hydroxybutyric acid) at an effective dose. Specifically, the present invention provides: a composition containing not less than 0.02 wt% of poly(D-3-hydroxybutyric acid); or pharmaceutical composition, a feed composition, and a food or beverage composition, which each contain not less than 0.2 wt% but less than 5.0 wt% or not less than 0.2 wt% but less than 2.0 wt% of poly(D-3-hydroxybutyric acid). The composition is characterized in that the poly(D-3-hydroxybutyric acid) is used such that intake of poly(D-3-hydroxybutyric acid) per day is 90 mg/m2body surface area or 900 mg/m2 body surface area or more.

IPC Classes  ?

• A61K 31/765 - Polymers containing oxygen
• A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 35/00 - Antineoplastic agents

Abstract

This gas measuring device for measuring gas in digestive organs of livestock includes a gas detecting means 1 and a gas collecting means 2, and is characterized in that: the gas collecting means 2 consists of a livestock in-body insertion part A having a gas suction location 22, and a livestock out-of-body part B which is continuous with the gas collecting means 1; a gas flow passage is formed from the gas suction location 22 to the gas detecting means 1; and the livestock in-body insertion part A is configured using a flexible tube having a shape retaining function.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

The methane gas produced during ruminant digestion is reduced by feeding the ruminant a feed containing unfermented coffee grounds.

IPC Classes  ?

• A23K 10/37 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms from waste material
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants

Abstract

The methane gas produced during ruminant digestion is reduced by feeding the ruminant a feed containing unfermented coffee grounds.

IPC Classes  ?

• A23K 10/37 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms from waste material
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants

Abstract

An oral drug includes powdered poly (R)-3-β-hydroxybutyric acid having a weight-average molecular weight of 10,000 to 700,000. The oral drug includes the powdered poly (R)-3-β-hydroxybutyric acid having (a) a purity of 70% or more and (b) a weight-average molecular weight of 10,000 to 590,000. The oral drug includes the powdered poly (R)-3-β-hydroxybutyric acid having (a) a purity of 90% or more and (b) a weight-average molecular weight of 10,000 to 590,000. An oral drug for increasing a ketone body concentration in blood that includes powdered poly (R)-3-β-hydroxybutyric acid having a weight-average molecular weight of 10,000 to 700,000. According to the present disclosure, an increased ketone body concentration in the blood is sustained for a longer period of time.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A23K 20/105 - Aliphatic or alicyclic compounds
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof

Abstract

Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The prevent invention provides an activated T cell in which the expression of an immune checkpoint molecule is suppressed, a method for producing the T cell, and a method for screening for a substance that can be used in the production of the T cell. Specifically, the prevent invention includes, as solving means, a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell, and a T cell produced or induced by the aforementioned method.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• C12N 9/10 - Transferases (2.)
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided are an evaluation method and an evaluation kit which are for an allergen inactivator and with which evaluation with accuracy and reproducibility can be carried out regardless of the types of test drugs to be evaluated or the accompanying components thereof.　This evaluation method for an allergen inactivator is characterized by comprising: a step for preparing an allergen-carrying membrane obtained by carrying an allergen on a membrane for carrying an allergen; a step for treating the allergen-carrying membrane with a test drug; a step for washing the allergen-carrying membrane treated with the test drug, and then treating the allergen-carrying membrane with an allergen-specific antibody; a step for washing the allergen-carrying membrane treated with the allergen-specific antibody, and detecting the specific antibody bound to the allergen; and a step for determining the degree of inactivation of the allergen by the test drug, on the basis of the detection amount of the specific antibody.

IPC Classes  ?

• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention addresses the problem of providing a composition containing lactic acid bacteria, said composition effectively suppressing the development of an allergy. More specifically, the present invention provides a composition that contains lactic acid bacteria belonging to the genus Lactobacillus animalus, said composition being provided as, for example, a food and drink composition, a pharmaceutical composition, an animal feed composition, or a composition for use in hygiene. The present invention further provides a method for preventing the development of an allergy.

IPC Classes  ?

• A61P 37/08 - Antiallergic agents
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A23K 10/12 - Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/9728 - Fungi, e.g. yeasts
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12R 1/145 - Clostridium
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

The present invention includes a poly(R)-3-β-hydroxybutyric acid powder having a weight average molecular weight of 10,000 to 700,000, inclusive. A poly(R)-3-β-hydroxybutyric acid powder having a purity of 70% or greater and a weight average molecular weight of 10,000 to 590,000, inclusive, may be included. A poly(R)-3-β-hydroxybutyric acid powder having a purity of 90% or greater and a weight average molecular weight of 10,000 to 590,000, inclusive, may be included. An oral drug for increasing the concentration of ketone bodies in blood, being a poly(R)-3-β-hydroxybutyric acid powder having a weight average molecular weight of 10,000 to 700,000, inclusive, may be included. According to the present invention, a state in which the concentration of ketone bodies in blood is increased is maintained for a longer period of time.

IPC Classes  ?

• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• C12P 7/26 - Ketones
• C12P 7/62 - Carboxylic acid esters
• A23K 20/105 - Aliphatic or alicyclic compounds
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• C12N 1/20 - BacteriaCulture media therefor
• A61K 33/24 - Heavy metalsCompounds thereof
• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 9/50 - Proteinases
• A61K 31/765 - Polymers containing oxygen
• A61K 35/74 - Bacteria

Abstract

The present invention improves the effect of radiotherapy.　This radiosensitizer for treating cancer contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the radiosensitizer being characterized by being used so that a compound represented by general formula (I) is administered to a patient in an amount of 8 mg/kg or less per dose. This radiosensitizer is also characterized by being used to repeat a set of the administration of the radiosensitizer and the irradiation with radiation immediately after the administration so that the total irradiation dose of radiation with respect to cancer is 10 Gy or greater.

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is an animal treatment instrument or the like by which side reactions are suppressed as compared to cases where light for treatment of a human is applied. This animal treatment instrument is provided with: a light source that is capable of outputting light to be applied to an animal and that has a peak wavelength in the range of 315-335 nm; and a support body that supports the light source.

IPC Classes  ?

• A61D 1/00 - Surgical instruments for veterinary use
• A61N 5/06 - Radiation therapy using light

Abstract

The present invention provides: an activated T cell in which the expression of an immune checkpoint molecule is suppressed; a method for preparing the T cell; and a method for screening a substance which is usable in preparing the T cell. More specifically, a means for solving the problem of the present invention comprises: a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, said method comprising reducing or losing the function of glucosylceramide synthase (UGCG) or a ganglioside of a T cell; and a T cell having been produced or induced by this method.

IPC Classes  ?

• C12N 15/54 - Transferases (2)
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 9/10 - Transferases (2.)

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/145 - Clostridium
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/74 - Bacteria
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/74 - Bacteria
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria

Abstract

The purpose of the present invention is to provide a primer set for PCR and LAMP to determine the type or subtype of a pathogen such as a virus, bacterium, or parasite, especially the subtype of an influenza virus, a method for determining the type or subtype using the primer set, and a kit for implementing the method. The present invention is a gene (RNA or DNA) that serves as a basis for classification of the type or subtype of a pathogen such as a virus, bacterium, or parasite, wherein all genes that belong to a type or subtype are divided into several small groups on the basis of the similarity of the base sequence, and the primers are designed so that the genes belonging to each small group can be detected by the smallest number of primers possible. The present invention is also a method for determining the type or subtype of a pathogen such as a virus, bacterium, or parasite that is the detection target by using primers prepared as described above.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention pertains to an autoimmune disease diagnosis method comprising a step for measuring a relative existing amount of bacteria included in a fecal sample collected from a test subject, and a step for performing the following (1) or (2): (1) when a relative existing amount of a bacteria, of which the base sequence of 16S-ribosomal RNA gene has an identity not lower than 99% with respect to the base sequence specified by SEQ ID NO: 3 or 4, is larger than the relative existing amount in a healthy individual, determining that the test subject is affected with, or has a high risk of being affected with an autoimmune disease; or (2) when a relative existing amount of a bacteria, of which the base sequence of 16S-ribosomal RNA gene has an identity not lower than 99% with respect to any one of the base sequences specified by SEQ ID NO: 5-23, is smaller than the relative existing amount in a healthy individual, determining that the test subject is affected with, or has a high risk of being affected with, an autoimmune disease.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 35/74 - Bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 37/02 - Immunomodulators
• C12Q 1/06 - Quantitative determination
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

　Provided are: a risk diagnosis method; preventive method; and method for inhibiting the progress of canine mitral insufficiency.　This risk diagnosis method for canine mitral insufficiency comprises: a step in which a sample taken from a canine subject is investigated to ascertain whether said sample includes Porphyromonas gulae type-C Fimbrillin (FimA) which contains the amino acid sequence of SEQ ID NO: 6; and a step in which if the sample contains Porphyromonas gulae type-C FimA, the canine subject is deemed to run a risk of having or developing mitral insufficiency.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 37/00 - Details not covered by any other group of this subclass

Abstract

Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

　Provided are a canine glaucoma susceptibility gene and a method for using the same. By analyzing and comparing single nucleotide polymorphism in dogs with glaucoma and normal dogs, it was discovered that an SNP (53096346, Val658Val) (CanFam3.1) on the newly discovered canine ADAMTS10 gene is effective in diagnosis.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided are a method for evaluating the malignancy of a malignant tumor in a non-human animal and a composition to be used for the evaluation. The method for evaluating the malignancy of a tumor in a non-human animal comprises: detecting CD34 that is expressed in cells of a tumor cell-containing sample derived from the subject animal; and, when the ratio of CD34-expressing cells to the total cells in the sample is at a preset level or higher, evaluating the tumor as malignant. Also provided is a diagnosis kit for evaluating the malignancy of a tumor in a non-human animal, said kit comprising an anti-CD34 antibody.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention addresses the problem of newly finding a compound that has no effect other than an effect of increasing cavernous pressure, different from conventional medicinal compositions for treating or ameliorating erectile dysfunction. The present inventors examined various substances derived from natural products with respect to the presence or absence of a male function-improving effect. As a result, they found that the administration of helipyrone A (3,3'-methylenebis(6-ethyl-4-hydroxy-5-methyl-2H-pyran-2-one)), which is a component derived from curry plant belonging to the genus Helichrysum of the family Asteraceae, enhances an cavernous nerve stimulation-induced cavernous pressure increasing effect in the corpus cavernosum of the penis, and thus completed the present invention.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• C12R 1/145 - Clostridium
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

　Provided are a method for detecting inflammatory bowel disease and a method for testing human salivary flora, whereby it is possible to conduct an accurate pathological evaluation with a simple test.　The base sequences of 16S ribosomal RNA genes from flora in a saliva sample taken from a test subject are determined at random to obtain a base sequence data set, and salivary analytes associated with inflammatory bowel disease are detected on the basis of the obtained base sequence data set. In such cases, it is preferable to use indices such as: the number of bacterial strains constituting the salivary flora, determined on the basis of the data set; the number of cluster groups based on the similarity between the base sequences included in the data set; the similarity distance between the group and a group of healthy subjects, determined on the basis of the data set; and the abundance of bacteria belonging to specific phyla, genera and species among the salivary flora, determined on the basis of the data set.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

　The present invention addresses the problem of providing a method for determining the pathogenic strength/weakness of bacteria transmitted in the case of canine periodontal disease.　The inventors of the present invention have found that the main pathogen for canine periodontal disease is a bacteria called Porphyromonas gulae, and furthermore have revealed Fimbrillin which is the protein forming the fimbriae of this bacteria, and fimA gene, the gene coding FimA, can be mainly classified into three groups, and that there is a correlation in the relevance of each group to the virulence of the bacteria causing periodontal disease, and thus accomplished the present invention.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/02 - Bacterial antigens
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• C12N 15/09 - Recombinant DNA-technology

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention addresses the problem of developing a method for predicting the quality of meat and a method for predicting shipment times in the cattle fattening stage; more specifically, a method for estimating, in the cattle fattening stage, shipment dates or BMS numbers, which influence the price of beef carcasses in markets. The inventors of the present invention discovered correlations between the contents of specific minerals contained in the coats of cattle and the quality of meat, as a result of diligently carrying out studies to solve said problem, revealing that, on the basis of the contents of the minerals, the quality of cattle meat or shipment times can be predicted in the latter stage of cattle fattening, thus demonstrating that the abovementioned problem can be solved.

IPC Classes  ?

• A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
• G01N 23/223 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material by irradiating the sample with X-rays or gamma-rays and by measuring X-ray fluorescence

Abstract

Provided are: a canine glaucoma disease susceptibility gene; and use of the gene. It is found that, among polymorphism sites which have been found to be different between a dog suffering from glaucoma and a normal dog as the result of the analysis and comparison of single nucleotide polymorphisms in the dogs, polymorphism sites numbered International single nucleotide polymorphism Nos. rs22018513 and rs22018514 are effective for the diagnosis of glaucoma.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention addresses the problem of developing a novel therapeutic agent for diabetes, which does not cause hypoglycemic symptoms as a side effect. The inventors of the invention made intensive studies, and as a result, the inventors revealed for the first time in the technical field that by orally administering infectious pinworm eggs to an animal, type 2 diabetes can be prevented or the onset thereof can be delayed in the body to which the eggs were administered. On the basis of the results, a pharmaceutical composition for preventing or delaying the onset of type 2 diabetes, containing infectious pinworm eggs, and a non-human animal model for studying diabetes, which is obtained by administering infectious pinworm eggs to a non-human animal model of diabetes can be provided.

IPC Classes  ?

• A61K 35/56 - Materials from animals other than mammals
• A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Conventional highly sensitive protein quantification methods using a spectrometer had the issue of sample loss and non-fragmentation rates during the process of fragmentation of the target protein not being corrected by internal standard peptide fragments. In addition, identification and/or quantification of posttranslational modification etc., of proteins using a spectrometer was extremely difficult. The present invention addresses the problem of developing a method for high-precision quantification of proteins using a spectrometer and identification and/or quantification of posttranslational modifications or genetic mutations in proteins.　The present inventors found that a plurality of target protein-derived peptide fragments can be detected at one time using the spectrometer and proteins can be quantified with high sensitivity and high precision, by using a stable isotope-labeled, internal standard protein. The present inventors also found that the posttranslational modifications and genetic mutations of each peptide fragment could be identified and/or quantified using the average quantification value for the detected target protein-derived peptide fragments.

IPC Classes  ?

• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

The present invention provides a prophylactic or therapeutic medicinal product or a supplement which is effective on corneal epithelium disorders and/or conjunctival epithelium disorders and is safe. Specifically provided is a therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders, which is characterized by comprising, as an active ingredient, eicosapentaenoic acid and/or docosahexaenoic acid, or a glycerin ester or a phospholipid which contains the fatty acid as a constituent fatty acid, or a lower-alcohol ester of the fatty acid. Preferably, the therapeutic or prophylactic agent contains EPA and/or DHA in the form of a purified fish oil or a purified krill oil. When the therapeutic or prophylactic agent is ingested at a daily dose of about 50-5000 mg in terms of the total amount of EPA and/or DHA or the ester thereof, corneal epithelium disorders and/or conjunctival epithelium disorders can be alleviated or the amount of tear can be recovered.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 35/60 - Fish, e.g. seahorsesFish eggs
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto.

IPC Classes  ?

• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A mouse pheromone containing ESP1, which has an effect of enhancing lordosis response in female mice and thus increasing mouse breeding efficiency.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

It is intended to provide a DNA construct such as a DNA fragment or an expression vector containing the DNA fragment capable of elucidating how alternative splicing of an exon of a gene specifying a protein to be alternatively spliced is regulated in cells. The present inventors elucidated that the above object can be achieved by inserting an intervening fragment containing a cloning region capable of inserting an exon of a gene specifying a protein to be alternatively spliced such that cDNA for a reporter protein is divided.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

It is intended to develop a method for reducing a noise from a non-target gene having a similar sequence and amplifying only a target gene and a novel quantitative method by obtaining a signal from the amplified gene with high accuracy (high sensitivity and high specificity). As a result of intensive studies made by the inventors of the invention, it was found that the object can be achieved by incorporating a third primer in a PCR reaction mixture, thus the invention has been completed.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

An anti-obesity agent comprising, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing a lipase having the amino acid sequence depicted in SEQ ID NO:1, 3 or 5 or an amino acid sequence having deletion, substitution or addition of one or more amino acid residues in the amino acid sequence depicted in SEQ ID NO:1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 35/74 - Bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/46 - Hydrolases (3)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/335 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Lactobacillus (G)
• C12N 9/14 - Hydrolases (3.)
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material